Transthyretin amyloid cardiomyopathy (ATTR-CM), once considered a rare disease, is now an increasingly recognized cause of heart failure. This rise in diagnoses is driven by increased awareness, the availability of non-invasive diagnostics, and the introduction of disease-modifying therapies (DMTs) in an aging populati...
Sophie I. van der Heide, A. C. Maanen, G. Lefeber et al.· Netherlands Heart Journal· 0 citations
Variations in ATTR-CM care across Europe highlight key areas for improvement and reveal where interventions could have the greatest impact, as differences in the number of specialized centers, variability in time to treatment initiation, and unequal access to therapies contribute to these disparities.
L. Kieviet, L. Rekker, D. Breucker et al.· European Heart Journal· 0 citations
This review provides a comprehensive overview of the diagnostic pathway, including (AI-enabled) electrocardiography analysis, (non-)invasive imaging modalities, biomarkers, and genetic testing, and emerging therapeutic strategies are discussed.
L. Kieviet, D. Ahmetagić, S. Muller et al.· Netherlands Heart Journal· 0 citations
BACKGROUND
In transthyretin amyloid cardiomyopathy, mitral regurgitation (MR) severity may be underestimated by conventional (semi-)quantitative echocardiographic criteria due to restrictive low-flow hemodynamics. We sought to define and validate disease-specific MR risk thresholds and compare their prognostic performa...
L. Hauptmann, C. Kronberger, S. Schwarting et al.· Circulation· 0 citations
Background Patients with heart failure with reduced ejection fraction (HFrEF) had higher readmission rates than those with normal ejection fractions, and readmission rates were highest in the first 30-days post-admission. About 30% of patients with decompensated heart failure also have type 2 diabetes mellitus (T2DM)....
R. Soerarso, D. Y. Hasanah, E. Yonas et al.· Cardiology Research· 0 citations
Modulation of integrin signalling represents a potential complementary therapeutic strategy in ATTR-CM beyond TTR suppression and actively drives cardiac amyloid deposition, and disruption of integrin αvβ3/FAK/Akt signalling links amyloid-ECM interactions to mitochondrial dysfunction.
Zeping Qiu, Yingze Fan, J. Qin et al.· European Heart Journal· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.